Patent ID: 8362028

Claim:
A method of treating a patient suffering from bipolar disorder, attention deficit disorder, or schizophrenia comprising administering an effective amount of a compound or pharmaceutically acceptable salt of Formula I to the patient, wherein Formula I is in which: R 1 and R 2 are each independently hydrogen, halogen, hydroxyl, C 1 -C 3 alkyl, C 1 -C 6 alkoxy, or C 1 -C 6 alkylester; or R 1 and R 2 are joined by a —O—CH 2 —O— group; R 3 is hydrogen or methoxy; R 4 and R 5 are independently methyl or hydrogen; or R 4 and R 5 are joined to form a 5-membered heterocyclic ring containing no additional heteroatoms; and R is (i) a group of the formula -AB, where A is —NR 6 —, —O—, —NR 6 (C═O)—, —S(O) m —, —CH 2 C(═O)—, —S(O) m NR 6 —, —NR 6 S(O) m —, —OS(O) m —, —NR 6 (S═O)NR 7 —, —O(C═O)—, or —NR 6 (C═O)NR 7 —, where m is 0, 1, or 2; —B is (phenyl)C 0 -C 2 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 2 alkyl, (pyrrolidinyl)C 0 -C 2 alkyl, (piperidinyl)C 0 -C 2 alkyl, (piperazinyl)C 0 -C 2 alkyl, (morpholinyl)C 0 -C 2 alkyl, (pyridyl)C 0 -C 2 alkyl, (thienyl)C 0 -C 2 alkyl, (pyrrolyl)C 0 -C 2 alkyl, (furanyl)C 0 -C 2 alkyl, (imidazolyl)C 0 -C 2 alkyl, (thiazolyl)C 0 -C 2 alkyl, (pyrimidinyl)C 0 -C 2 alkyl, or (pyrazinyl)C 0 -C 2 alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from halogen, hydroxyl, amino, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, mono- and di-(C 1 -C 4 alkyl)amino, C 1 -C 2 haloalkyl, or C 1 -C 2 haloalkoxy; (iii) a 5-membered heteroaryl group having at least one nitrogen ring member, and 0, 1, or 2 additional ring members independently selected from the group consisting of N, O, and S, wherein the 5-membered heteroaryl group is attached via a nitrogen atom and is substituted with 0 to 3 substituents independently selected from the group consisting of halogen, hydroxyl, amino, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, mono- and di-(C 1 -C 4 alkyl)amino, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy; or (iv) a 5- or 6-membered heterocycloalkyl group linked via a nitrogen atom, wherein the heterocycloalkyl is substituted with from 0 to 4 substituents independently selected from the group consisting of halogen, hydroxyl, amino, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 alkylester, mono- and di-(C 1 -C 4 alkyl)amino, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, and 5- and 6-membered heterocycloalkyl; where R 6 , R 7 , R 8 , R 9 , and R 10 are each independently hydrogen, or C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 2 -C 4 alkanoyl, (C 3 -C 10 cycloalkyl)C 0 -C 8 alkyl, (heterocycloalkyl)C 0 -C 8 alkyl, or phenyl each of which is substituted with from 0 to 4 substituents independently selected from the group consisting of halogen, hydroxyl, amino, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, mono- and di-(C 1 -C 4 alkyl)amino, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy.